Challenges and Opportunities with Checkpoint Inhibition for First-Line Management of Advanced NSCLC: A Care Team Forum℠

Program Overview

This activity was designed to improve the knowledge and competence of clinicians with respect to biomarker testing, selection of first-line checkpoint inhibitor therapy, and management of immunotherapy-related adverse events in patients with advanced NSCLC.

Credit Expired
0.75 CE Credit(s)
Expires: October 18, 2022

Target Audience

This activity is intended for medical oncology, pathology, and pulmonology clinicians who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ evidence-based biomarker testing for patients with NSCLC
  • Select first-line checkpoint inhibitor therapy based on scientific evidence and therapeutic indications for patients with NSCLC
  • Apply evidence-based strategies for the management of immunotherapy-related adverse events in patients with NSCLC

Activity Faculty


Solange Peters, MD, PhD

Chair and Professor, Medical Oncology
University Hospital of Lausanne
Lausanne, Switzerland

Kerr, Keith - Headshot

Prof. Keith M. Kerr, FRCPath

Honorary Chair, Department of Pathology
Aberdeen University School of Medicine
Aberdeen Royal Infirmary
Foresterhill, Aberdeen,
Scotland, United Kingdom

Ramalingam - Headshot

Suresh S. Ramalingam, MD, FACP, FASCO

Professor, Hematology and Medical Oncology
Roberto C. Goizueta Chair, Cancer Research
Director, Division of Medical Oncology
Assistant Dean, Cancer Research
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, United States

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources